Anabolic Therapies for Osteoporosis

Endocrinology and Metabolism Clinics of North America

Volumn 41, Issue 3, 2012, Pages 507-525

  Uihlein, Alexander V ^a   Leder, Benjamin Z ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Anabolic therapy; Bone mineral density; Osteoporosis; Parathyroid hormone; Teriparatide

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; DICKKOPF 1 PROTEIN; GLUCOCORTICOID; PARATHYROID GLAND HORMONE; PARATHYROID HORMONE; PARATHYROID HORMONE RELATED PROTEIN [1-36]; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; SCLEROSTIN; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

BONE DENSITY; BONE METABOLISM; BONE STRENGTH; BONE TURNOVER; COMPARATIVE EFFECTIVENESS; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; FRACTURE; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; KIDNEY CALCIFICATION; KIDNEY FUNCTION; LEG CRAMP; MEN'S HEALTH; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROLITHIASIS; NONHUMAN; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; RHEUMATIC DISEASE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

ALENDRONATE; ANABOLIC AGENTS; ANIMALS; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; DRUG MONITORING; DRUG THERAPY, COMBINATION; DRUGS, INVESTIGATIONAL; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; OSTEOSARCOMA; TERIPARATIDE;

EID: 84864825624     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2012.05.002     Document Type: Review

References (81)

1. Riggs B.L., Hodgson S.F., O'Fallon W.M., et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990, 322:802-809.
2. Bauer W., Aub J.C., Albright F. Studies of calcium and phosphorus metabolism: V. A study of the bone trabeculae as a readily available reserve supply of calcium. J Exp Med 1929, 49:145-162.
3. Reeve J., Hesp R., Williams D., et al. Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis. Lancet 1976, 1:1035-1038.
4. Reeve J., Meunier P.J., Parsons J.A., et al. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br Med J 1980, 280:1340-1344.
5. Slovik D.M., Rosenthal D.I., Doppelt S.H., et al. Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxyvitamin D. J Bone Miner Res 1986, 1:377-381.
6. Reeve J., Davies U.M., Hesp R., et al. Treatment of osteoporosis with human parathyroid peptide and observations on effect of sodium fluoride. BMJ 1990, 301:314-318.
7. Hesch R.D., Busch U., Prokop M., et al. Increase of vertebral density by combination therapy with pulsatile 1-38hPTH and sequential addition of calcitonin nasal spray in osteoporotic patients. Calcif Tissue Int 1989, 44:176-180.
8. Finkelstein J.S., Klibanski A., Schaefer E.H., et al. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med 1994, 331:1618-1623.
9. Hodsman A.B., Fraher L.J., Ostbye T., et al. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis. J Clin Invest 1993, 91:1138-1148.
10. Tam C.S., Heersche J.N., Murray T.M., et al. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology 1982, 110:506-512.
11. Neer R.M., Arnaud C.D., Zanchetta J.R., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434-1441.
12. Jilka R.L., Weinstein R.S., Bellido T., et al. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999, 104:439-446.
13. Jilka R.L., O'Brien C.A., Ali A.A., et al. Intermittent PTH stimulates periosteal bone formation by actions on post-mitotic preosteoblasts. Bone 2009, 44:275-286.
14. Dobnig H., Turner R.T. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 1995, 136:3632-3638.
15. Bellido T., Ali A.A., Gubrij I., et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 2005, 146:4577-4583.
16. Drake M.T., Srinivasan B., Modder U.I., et al. Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 2010, 95:5056-5062.
17. Monroe D.G., McGee-Lawrence M.E., Oursler M.J., et al. Update on Wnt signaling in bone cell biology and bone disease. Gene 2012, 492:1-18.
18. Bikle D.D., Sakata T., Leary C., et al. Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone. J Bone Miner Res 2002, 17:1570-1578.
19. McCarthy T.L., Centrella M., Canalis E. Parathyroid hormone enhances the transcript and polypeptide levels of insulin-like growth factor I in osteoblast-enriched cultures from fetal rat bone. Endocrinology 1989, 124:1247-1253.
20. Oreffo R.O., Mundy G.R., Seyedin S.M., et al. Activation of the bone-derived latent TGF beta complex by isolated osteoclasts. Biochem Biophys Res Commun 1989, 158:817-823.
21. Glover S.J., Eastell R., McCloskey E.V., et al. Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone 2009, 45:1053-1058.
22. McClung M.R., San Martin J., Miller P.D., et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 2005, 165:1762-1768.
23. Greenspan S.L., Bone H.G., Ettinger M.P., et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 2007, 146:326-339.
24. Finkelstein J.S., Wyland J.J., Lee H., et al. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 2010, 95:1838-1845.
25. Black D.M., Greenspan S.L., Ensrud K.E., et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003, 349:1207-1215.
26. Cosman F., Eriksen E.F., Recknor C., et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res 2011, 26:503-511.
27. Body J.J., Gaich G.A., Scheele W.H., et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002, 87:4528-4535.
28. Jiang Y., Zhao J.J., Mitlak B.H., et al. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003, 18:1932-1941.
29. Dempster D.W., Cosman F., Kurland E.S., et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001, 16:1846-1853.
30. Lindsay R., Zhou H., Cosman F., et al. Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res 2007, 22:495-502.
31. Lindsay R., Cosman F., Zhou H., et al. A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. J Bone Miner Res 2006, 21:366-373.
32. Recker R.R., Bare S.P., Smith S.Y., et al. Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1-84. Bone 2009, 44:113-119.
33. Keaveny T.M., Donley D.W., Hoffmann P.F., et al. Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Miner Res 2007, 22:149-157.
34. Keaveny T.M., Hoffmann P.F., Singh M., et al. Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans. J Bone Miner Res 2008, 23:1974-1982.
35. Macdonald H.M., Nishiyama K.K., Hanley D.A., et al. Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis. Osteoporos Int 2011, 22:357-362.
36. Weinstein R.S. Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med 2011, 365:62-70.
37. Saag K.G., Shane E., Boonen S., et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007, 357:2028-2039.
38. Lane N.E., Sanchez S., Modin G.W., et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 1998, 102:1627-1633.
39. Orwoll E.S., Scheele W.H., Paul S., et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003, 18:9-17.
40. Kaufman J.M., Orwoll E., Goemaere S., et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 2005, 16:510-516.
41. Finkelstein J.S., Hayes A., Hunzelman J.L., et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003, 349:1216-1226.
42. Kurland E.S., Cosman F., McMahon D.J., et al. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000, 85:3069-3076.
43. Yu E.W., Neer R.M., Lee H., et al. Time-dependent changes in skeletal response to teriparatide: escalating vs. constant dose teriparatide (PTH 1-34) in osteoporotic women. Bone 2011, 48:713-719.
44. Black D.M., Bouxsein M.L., Palermo L., et al. Randomized trial of once-weekly parathyroid hormone (1-84) on bone mineral density and remodeling. J Clin Endocrinol Metab 2008, 93:2166-2172.
45. Cosman F., Nieves J., Zion M., et al. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 2005, 353:566-575.
46. Finkelstein J.S., Wyland J.J., Leder B.Z., et al. Effects of teriparatide retreatment in osteoporotic men and women. J Clin Endocrinol Metab 2009, 94:2495-2501.
47. Cosman F., Nieves J.W., Zion M., et al. Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate. J Bone Miner Res 2009, 24:1110-1115.
48. Cosman F., Lane N.E., Bolognese M.A., et al. Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2010, 95:151-158.
49. Matsumoto T., Shiraki M., Hagino H., et al. Daily nasal spray of hPTH(1-34) for 3 months increases bone mass in osteoporotic subjects: a pilot study. Osteoporos Int 2006, 17:1532-1538.
50. Lindsay R., Nieves J., Formica C., et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997, 350:550-555.
51. Cosman F., Nieves J., Woelfert L., et al. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 2001, 16:925-931.
52. Ste-Marie L.G., Schwartz S.L., Hossain A., et al. Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy. J Bone Miner Res 2006, 21:283-291.
53. Deal C., Omizo M., Schwartz E.N., et al. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 2005, 20:1905-1911.
54. Finkelstein J.S., Leder B.Z., Burnett S.M., et al. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metab 2006, 91:2882-2887.
55. Cosman F., Wermers R.A., Recknor C., et al. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab 2009, 94:3772-3780.
56. Ettinger B., San Martin J., Crans G., et al. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004, 19:745-751.
57. Obermayer-Pietsch B.M., Marin F., McCloskey E.V., et al. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 2008, 23:1591-1600.
58. Blumsohn A., Marin F., Nickelsen T., et al. Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide. Osteoporos Int 2011, 22:1935-1946.
59. Miller P.D., Delmas P.D., Lindsay R., et al. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab 2008, 93:3785-3793.
60. Rittmaster R.S., Bolognese M., Ettinger M.P., et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 2000, 85:2129-2134.
61. Lindsay R., Scheele W.H., Neer R., et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 2004, 164:2024-2030.
62. Black D.M., Bilezikian J.P., Ensrud K.E., et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 2005, 353:555-565.
63. Vahle J.L., Sato M., Long G.G., et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 2002, 30:312-321.
64. Sato M., Vahle J., Schmidt A., et al. Abnormal bone architecture and biomechanical properties with near-lifetime treatment of rats with PTH. Endocrinology 2002, 143:3230-3242.
65. Vahle J.L., Long G.G., Sandusky G., et al. Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol 2004, 32:426-438.
66. Jolette J., Wilker C.E., Smith S.Y., et al. Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats. Toxicol Pathol 2006, 34:929-940.
67. Vahle J.L., Zuehlke U., Schmidt A., et al. Lack of bone neoplasms and persistence of bone efficacy in cynomolgus macaques after long-term treatment with teriparatide [rhPTH(1-34)]. J Bone Miner Res 2008, 23:2033-2039.
68. Harper K.D., Krege J.H., Marcus R., et al. Osteosarcoma and teriparatide?. J Bone Miner Res 2007, 22:334.
69. Subbiah V., Madsen V.S., Raymond A.K., et al. Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporos Int 2010, 21:1041-1045.
70. Khosla S., Westendorf J.J., Oursler M.J. Building bone to reverse osteoporosis and repair fractures. J Clin Invest 2008, 118:421-428.
71. Costa A.G., Bilezikian J.P. Sclerostin: therapeutic horizons based upon its actions. Curr Osteoporos Rep 2012, 10:64-72.
72. Li X., Ominsky M.S., Niu Q.T., et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 2008, 23:860-869.
73. Li X., Ominsky M.S., Warmington K.S., et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009, 24:578-588.
74. Ominsky M.S., Vlasseros F., Jolette J., et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 2010, 25:948-959.
75. Ominsky M.S., Li C., Li X., et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of non-fractured bones. J Bone Miner Res 2010, 26:1012-1021.
76. Li X., Ominsky M.S., Warmington K.S., et al. Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats. Endocrinology 2011, 152:3312-3322.
77. Padhi D., Jang G., Stouch B., et al. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011, 26:19-26.
78. Morvan F., Boulukos K., Clement-Lacroix P., et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res 2006, 21:934-945.
79. Wang F.S., Ko J.Y., Lin C.L., et al. Knocking down dickkopf-1 alleviates estrogen deficiency induction of bone loss. A histomorphological study in ovariectomized rats. Bone 2007, 40:485-492.
80. Betts A.M., Clark T.H., Yang J., et al. The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis. J Pharmacol Exp Ther 2010, 333:2-13.
81. Horwitz M.J., Tedesco M.B., Gundberg C., et al. Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2003, 88:569-575.